



STATUS EPILEPTICUS Pathway



Provisional diagnosis	
Duration of previous hospitalization (if any)	
Previous lab investigations if any	

CO-MORBIDS	<input type="checkbox"/> Hypertension	<input type="checkbox"/> AF	<input type="checkbox"/> COPD
	<input type="checkbox"/> Type 2 Diabetes Mellitus	<input type="checkbox"/> Anticoagulation	<input type="checkbox"/> CLD
	<input type="checkbox"/> CAD	<input type="checkbox"/> CKD	<input type="checkbox"/> Recent Surgery

Recognize

STATUS EPILEPTICUS

- Seizures with 5 minutes or more of continuous clinical and/or
- Electrographic seizure activity
- OR
- Recurrent seizure activity without recovery between

Immediate General Assessment and stabilization

- A: Airway - Assess and maintain patent airway (ETI/MV)
- B: Breathing - Assess and administer oxygen if required; aim SpO₂ ≥ 95%
- C: Circulation - Vascular access, blood collection,
 - Send for Blood glucose/CBC/RFT/Mg²⁺ & PO₄⁻/LFT/ /PT, INR, APTT
 - Obtain anticonvulsant levels for established seizure patients
 - Toxicology Screening & HcG
- Inform Neurology team.
- 12 lead ECG
- Emergent Non Contrast CT/MRI of brain
- Correct reversible causes like hyponatremia & hypoglycemia
- In case of hypoglycaemia, rule out possibility of thiamine deficiency, **administer dextrose before thiamine.**

- ❑ Review patient History, medications and procedures
- ❑ Establish time of symptom onset or last known normal
- ❑ Perform Neurological Examination

Management:

IV access?

No

Yes

❑ Midazolam intramuscular (IM) 0.15 mg/kg (max 10 mg)

❑ Diazepam rectal gel (PR) • 0.2 mg/kg

❑ Lorazepam IV 0.1 mg/kg (max 4 mg) Or

❑ Diazepam IV 0.2 mg/kg (max 10 mg)
Repeat after 4min if seizures do not resolve after first dose.

If seizures persist choose 2nd line drugs

❑ Phenytoin

❑ Levetiracetam

❑ Valproic acid

For doses look at Appendix

Reassess Patient:

❑ **Refractory Status Epilepticus (RSE)**
If seizures persist despite early benzodiazepines and one additional first-line anti-seizure medication

Administer Loading dose of an alternative second line medication.

If seizures persist, consider a **continuous infusion agent**.

Consult neurology and continuous EEG monitoring if available.

Infusion Agent:

❑ Propofol

❑ Midazolam

❑ Ketamine

❑ Pentobarbital

(For dose – Appendix)

❑ Super Refractory Status Epilepticus (SRSE):

If seizures cannot be terminated with the use of an intravenous (IV) anesthetic in addition to benzodiazepines and standard anticonvulsants.

Management of SRSE:

Non-surgical

- ❑ Immunotherapy- for selected cases after discussing with the specialist- 1 g IV methylprednisolone for 3 to 7 days, OR Plasma exchange or IV immunoglobulins over 3 to 5 sessions •
- ❑ Longstanding-immunotherapy
 - prednisone
 - Rituximab and cyclophosphamide.
 -
- ❑ Ketogenic diet (4:1 ratio of fat-to-carbohydrate and protein)
- ❑ Therapeutic hypothermia (TH)
- ❑ Electroconvulsive therapy- selected Cases

Surgical intervention

- ❑ For known etiologic structural lesion, early neurosurgical consultation is recommended.
- Electrical stimulation therapies:**
 - ❑ Vagal nerve stimulator placement has been described in the treatment of SRSE.
 - ❑ Deep brain stimulation
 - ❑ Responsive neurostimulation

ICU Days	EVENTS / SUPPORTS				
1	<input type="checkbox"/> MV	<input type="checkbox"/> RRT	<input type="checkbox"/> Vasopressors	<input type="checkbox"/> Organ dysfunction	<input type="checkbox"/> Others
2	<input type="checkbox"/> MV	<input type="checkbox"/> RRT	<input type="checkbox"/> Vasopressors	<input type="checkbox"/> Organ dysfunction	<input type="checkbox"/> Others
3	<input type="checkbox"/> MV	<input type="checkbox"/> RRT	<input type="checkbox"/> Vasopressors	<input type="checkbox"/> Organ dysfunction	<input type="checkbox"/> Others
4	<input type="checkbox"/> MV	<input type="checkbox"/> RRT	<input type="checkbox"/> Vasopressors	<input type="checkbox"/> Organ dysfunction	<input type="checkbox"/> Others
5	<input type="checkbox"/> MV	<input type="checkbox"/> RRT	<input type="checkbox"/> Vasopressors	<input type="checkbox"/> Organ dysfunction	<input type="checkbox"/> Others
6	<input type="checkbox"/> MV	<input type="checkbox"/> RRT	<input type="checkbox"/> Vasopressors	<input type="checkbox"/> Organ dysfunction	<input type="checkbox"/> Others
7	<input type="checkbox"/> MV	<input type="checkbox"/> RRT	<input type="checkbox"/> Vasopressors	<input type="checkbox"/> Organ dysfunction	<input type="checkbox"/> Others
>7 days Course of illness					

Outcome

- I. APACHE II/IV Score: _____ 2. SOFA Score at the time of admission: _____ , 48hr: _____
 at the time of transfer out / LAMA / Discharge: _____ 3. Length of ICU Stay: _____
 4.Length of Hospital stay: _____
- II. Organ Failure : AKI Liver failure Coagulopathy Encephalopathy
Myocardial Dysfunction CIPNM MV dependent
- III. Renal replacement therapy _____ day from CRRT / SLED
- IV. MV _____ duration Prone ECMO Tracheostomy
- V. Outcome: Death Survived (Discharged from ICU / Transfer out to stepdown / HDU/
 Room) LAMA

Ambulated Bed ridden (with support / without support)

Doctor Name: _____, Sign: _____

Appendix:

Drug doses

Second line agents

1. PHENYTOIN – 20 MG /KG IV UPTO 25TO 50 MG /MIN ;100 MG IV 8TH HOURLY OR
2. LEVETIRACETAM – 40TO 60 MG /KG IV UPTOA TOTAL OF 4.5 GM OVER 15 MINUTES ,500 – 1000 MG 12TH HOURLY OR.
3. VALPROICACID – 30 MG /KG IV UPTO 10 MG / KG /MIN ; 500 MG IV 12TH HOURLY
4. LACOSAMIDE - 200 - 400 MG IV BOLUS, 200 MG IV 12TH HOURLY OR
5. TOPIRAMATE - 200 – 400 MG PO BOLUS, 300 MG PO 6TH HOURLY OR
6. GABAPENTIN - 300-900 MG PO BOLUS, 300 – 900 MG PO 8TH HOURLY

Continuous infusion agent dosing

1. PROPOFOL -2-5 MG / KG IV BOLUS ; 0.2-2 MG /KG / HR IV INFUSION
2. MIDAZOLAM – 0.1 – 0.3 MG / KG IV BOLUS ;5-30 MG /KG / HR IV INFUSION
3. KETAMINE – 1-3 MG / KG IV BOLUS ;0.5 – 10 MG / KG /HR INFUSION
4. PENTOBARBITAL – 5-10 MG / KG BOLUS ;0.5-5 MG / KG /HR INFUSION

SPARSH CRITICAL CARE

Author	Supervised by	Version/Date	Review Date
Dr. Taher Ahmed MD, IDCCM	Dr. Masood Mohammed MD,MRCP(UK),EDIC,FICCM(UK)	1.0/28-02-2023	28-02-2025